Aquestive Therapeutics
Aquestive Therapeutics

Aquestive Therapeutics

Pharmaceuticals
WebsiteInvestor RelationsSEC
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

$621.3M

Market Cap • 9/22/2026

2017

(9 years)

Founded

2018

(8 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

11,5

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

621,3M

EV

581,8M

EV/Revenue

10,8

EV/EBITDA

-11,1

EV/EBIT

-11

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-14%

Total Yield

-14%

Payout

0%

Retained Earnings

-477,9M

Profitability

Gross Margin

67%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

29,4%

Capex/Revenue

1,1%

Capex/D&A

112,7%

Capex/OCF

-1,3%

SBC/OCF

—

% PPE

9%

% Goodwill

0%

ROE

121,1%

ROIC

—

Growth

CAGR Revenue 5Y

5,3%

CAGR Op. Income 5Y

3,5%

CAGR Net Income 5Y

4,1%

CAGR EPS 5Y

-18,7%

CAGR OCF 5Y

3,8%

Leverage

N.D./EBITDA

0,8

Debt/Equity

0%

Current Ratio

7,2

Quick Ratio

6,5

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium